Cite
Wiedmann F, Beyersdorf C, Zhou XB, et al. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. Cardiovasc Res. 2021;doi: 10.1093/cvr/cvab177.
Wiedmann, F., Beyersdorf, C., Zhou, X. B., Kraft, M., Paasche, A., Jávorszky, N., Rinné, S., Sutanto, H., Büscher, A., Foerster, K. I., Blank, A., El-Battrawy, I., Li, X., Lang, S., Tochtermann, U., Kremer, J., Arif, R., Karck, M., Decher, N., van Loon, G., Akin, I., Borggrefe, M., Kallenberger, S., Heijman, J., Haefeli, W. E., Katus, H. A., & Schmidt, C. (2021). Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. Cardiovascular research, . https://doi.org/10.1093/cvr/cvab177
Wiedmann, Felix, et al. "Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy." Cardiovascular research vol. (2021). doi: https://doi.org/10.1093/cvr/cvab177
Wiedmann F, Beyersdorf C, Zhou XB, Kraft M, Paasche A, Jávorszky N, Rinné S, Sutanto H, Büscher A, Foerster KI, Blank A, El-Battrawy I, Li X, Lang S, Tochtermann U, Kremer J, Arif R, Karck M, Decher N, van Loon G, Akin I, Borggrefe M, Kallenberger S, Heijman J, Haefeli WE, Katus HA, Schmidt C. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. Cardiovasc Res. 2021 May 24; doi: 10.1093/cvr/cvab177. Epub 2021 May 24. PMID: 34028533.
Copy
Download .nbib